Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Ferrarotti (Pavia, Italy), S. Ottaviani (Pavia, Italy), E. Paracchini (Veruno, Italy), D. Piloni (Pavia, Italy), F. Mariani (Pavia, Italy), G. Paone (Rome, Italy), A. Balderacchi (Pavia, Italy), V. Barzon (Pavia, Italy), M. Bosio (Pavia, Italy), Z. Kadija (Pavia, Italy), B. Balbi (Veruno, Italy), A. Corsico (Pavia, Italy). Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management. 4063

Member's Comments

No comment yet.

Related content which might interest you: Expanding the awareness of Alpha-1 antitrypsin deficiency (AATD) to provide a multidisciplinary approach to care Source: Virtual Congress 2020 – Airway diseases Year: 2020 Molecular characterization of novel PiS-like alleles identified in Spanish patients with Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018 Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe dyspnea Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Translational immunology in genetic lung disease: advances in cystic fibrosis and Alpha-1 anti-trypsin deficiency Source: International Congress 2014 – From bench to bronchiole: translational immunology and airways disease Year: 2014 Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Diagnosis and management of alpha1-antitrypsin deficiency Source: Breathe 2007; 4: 38-46 Year: 2007 Substitution therapy in Alpha-1 antitrypsin deficiency after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006 Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content Year: 2018 Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Hereditary alpha1-antitrypsin deficiency in children and its clinical consequences Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013 Endobronchial valve treatment in patients with severe emphysema due to alpha-1 antitrypsin deficiency. Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021